Cargando…
Reply to Watchorn et al.: Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
Autores principales: | Foer, Dinah, Beeler, Patrick E., Cui, Jing, Karlson, Elizabeth W., Bates, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017586/ https://www.ncbi.nlm.nih.gov/pubmed/33508207 http://dx.doi.org/10.1164/rccm.202012-4511LE |
Ejemplares similares
-
Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
por: Foer, Dinah, et al.
Publicado: (2021) -
Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
por: Watchorn, David, et al.
Publicado: (2021) -
Reply to Butler et al.
por: Eskandari, Mona, et al.
Publicado: (2023) -
In Reply to ‘Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?’
por: Leehey, David J.
Publicado: (2021) -
Reply to Gueret et al. and to Hammond et al.
por: Brown, Ryan M., et al.
Publicado: (2020)